Lead Product(s): Alfacalcidol
Therapeutic Area: Nephrology Product Name: One-Alpha
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Cheplapharm Arzneimittel Gmbh
Deal Size: $357.0 million Upfront Cash: Undisclosed
Deal Type: Divestment August 31, 2020
The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.